WO2017061787A1 - Composition pour soulager la gueule de bois contenant un polysaccharide extracellulaire fabriqué à partir de ceriporia lacerata comme principe actif - Google Patents

Composition pour soulager la gueule de bois contenant un polysaccharide extracellulaire fabriqué à partir de ceriporia lacerata comme principe actif Download PDF

Info

Publication number
WO2017061787A1
WO2017061787A1 PCT/KR2016/011183 KR2016011183W WO2017061787A1 WO 2017061787 A1 WO2017061787 A1 WO 2017061787A1 KR 2016011183 W KR2016011183 W KR 2016011183W WO 2017061787 A1 WO2017061787 A1 WO 2017061787A1
Authority
WO
WIPO (PCT)
Prior art keywords
laccerata
culture medium
extracellular polysaccharide
mycelium culture
hangover
Prior art date
Application number
PCT/KR2016/011183
Other languages
English (en)
Korean (ko)
Inventor
김윤수
윤성균
유혜동
신은지
Original Assignee
(주)퓨젠바이오농업회사법인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)퓨젠바이오농업회사법인 filed Critical (주)퓨젠바이오농업회사법인
Publication of WO2017061787A1 publication Critical patent/WO2017061787A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts

Definitions

  • the present invention is an active ingredient produced by Ceriporia lacerata ( Ceriporia lacerata ), the mycelium culture medium of the Ceriporia laccerata containing the active ingredient, the dry powder of the mycelium culture solution or the extract of the mycelium culture medium active ingredient It relates to a composition for hangover relief to contain.
  • "hangover” refers to a phenomenon in which the head is heavy, ill or sore due to drinking, which is caused by the poisoning effect of ethanol or acetaldehyde accumulated in hepatocytes. . If these substances accumulate in liver cells for a long time and cause poisoning, fatigue, abdominal bloating, and vomiting may occur.
  • the ethyl alcohol introduced into the body is absorbed by the gastrointestinal or small intestine and enters the blood vessels and is transferred to the liver.
  • hepatocytes have alcohol dehydrogenase (ADH) to oxidize alcohol to acetaldehyde, and the acetaldehyde is decomposed to acetic acid by acetaldehyde dehydrogenase (ALDH) in hepatocytes.
  • ADH alcohol dehydrogenase
  • ADH acetaldehyde dehydrogenase
  • the decomposed product is transferred to muscle or adipose tissue of the whole body and finally decomposed into carbon dioxide gas and water.
  • Acetaldehyde dehydrogenases include type II which initiates oxidation even at low concentrations of acetaldehyde and type I which initiates oxidation only at high concentrations of acetaldehyde.
  • Asians are generally deficient in type II acetaldehyde dehydrogenase, which slows the oxidation of acetaldehyde, and thus causes various hangovers due to normal metabolism caused by unoxidized acetaldehyde and / or ethyl alcohol. .
  • ethanol is the main ingredient of alcohol
  • ingested ethanol is absorbed through the small intestine and digestive tract, and blood alcohol concentration reaches its highest between 20 and 120 minutes after ingestion.
  • This absorbed ethanol is metabolized in all organs, including the liver, about 10% of which is excreted in breathing, or in urine and sweat, and most of it is broken down in the liver.
  • Ethanol degradation in the liver is the main metabolism of conversion to acetaldehyde through oxidation. This is done by three reactive enzyme systems: ADH, microsomal ethanol-oxidizing system and catalase (K. Ebihara et al. , Agri . Biol . Chem . , 52, 1311, 1988). . As described above, various toxicological studies of ethanol have been conducted as well as toxicological studies. It has been reported that toxicities of ethanol not only affect neurological aspects but also genetics (J. Caballeria, et al. , Life Sci. , 41, 1021-1727, 1986).
  • Korean Patent No. 10-0968109 discloses a hangover relief composition comprising a natural extract and a calcium compound and a method of manufacturing the same.
  • Ceriporia laccerata is a type of white fungus and is known to perform co-metabolism called lignin decomposition in order to use carbon sources such as cellulose, hemicellulose, other polysaccharides, and glycerol in an ecosystem.
  • the present inventors have completed the present invention by confirming that the mycelial culture solution, the dry powder or extract thereof, of the active ingredient isolated from Seriphoria laccerata, the same, and the Seriphoria laccerata, exhibit a hangover effect.
  • Another object of the present invention is to provide the use of the active ingredient produced by Ceriporia laccerata for use in the manufacture of a pharmaceutical composition for preventing or relieving hangovers.
  • the present invention is an extracellular polysaccharide produced by Seriphoria laccerata, mycelium culture medium of the Seriphoria laccerata comprising the extracellular polysaccharide, dry powder of the mycelium culture medium or the mycelium culture medium It provides a pharmaceutical composition for preventing or resolving hangover, containing the extract of as an active ingredient.
  • the present invention is an extracellular polysaccharide produced by Seriphoria laccerata, mycelium culture medium of the Seriporia laccerata containing the extracellular polysaccharide, the dry powder of the mycelium culture medium or the extract of the mycelium culture medium active ingredient Provided as a health functional food for preventing or improving hangovers.
  • the present invention requires an extracellular polysaccharide produced by Seriphoria laccerata, mycelium culture medium of the Seriphoria laccerata containing the extracellular polysaccharide, a dry powder of the mycelium culture medium or an extract of the mycelium culture medium. It provides a hangover prevention or remedy comprising administering to a subject.
  • the present invention is an extracellular polysaccharide produced by Ceriporia laccerata for use in the manufacture of a pharmaceutical composition for preventing or eliminating hangovers, a mycelium culture solution of a Ceriporia laccerata comprising the extracellular polysaccharide, It provides a dry powder of the mycelium culture medium or the use of the extract of the mycelium culture medium.
  • the present invention contains an extracellular polysaccharide produced by Seriphoria laccerata, a mycelium culture medium of the Seriphoria laccerata containing the extracellular polysaccharide, a dry powder of the mycelium culture medium, or an extract of the mycelium culture medium as an active ingredient.
  • the pharmaceutical composition and health functional food for preventing or eliminating hangovers exhibit an excellent hangover effect by reducing ethanol and / or acetaldehyde in the blood.
  • Figure 1 shows the results of measuring the blood alcohol concentration of the mice after treatment of the culture medium of the seriporia laccerata mycelium administered to the ethanol.
  • Figure 2 is a result of measuring the hangover resolution of the seriporia lacserata mycelium culture solution through a simple clinical experiment.
  • the present invention contains an extracellular polysaccharide produced by Seriphoria laccerata, a mycelium culture medium of the Seriphoria laccerata containing the extracellular polysaccharide, a dry powder of the mycelium culture medium or an extract of the mycelium culture medium as an active ingredient.
  • an extracellular polysaccharide produced by Seriphoria laccerata
  • a mycelium culture medium of the Seriphoria laccerata containing the extracellular polysaccharide
  • a dry powder of the mycelium culture medium or an extract of the mycelium culture medium as an active ingredient.
  • extracellular polysaccharide is a part of the cell wall of a microorganism such as a fungus, and the polysaccharide is secreted to the outside of the cell to form a capillary around it or secreted into the periphery or medium as a slime. Means.
  • the extracellular polysaccharide is secreted by the microorganism to protect itself from the external environment such as antibodies, toxic substances, protozoa and bacteriophage.
  • the extracellular polysaccharide is 40 to 60% by weight of sugar and 30 to 40% by weight of protein, 40 to 50% by weight of sugar and 32 to 38% by weight of protein, 43 to 47% by weight of sugar and 33 to 36% by weight Protein, and more specifically about 45% by weight of sugar and about 34% by weight of protein.
  • the sugar may contain mannose, galactose and glucose.
  • the extracellular polysaccharide may have a molecular weight of 100 ⁇ 150 kDa, 110 ⁇ 140 kDa or 115 ⁇ 125 kDa, more specifically may have a molecular weight of about 120 kDa.
  • the extracellular polysaccharide (a) liquid culture of the mycelium of Seriporia laccerata to prepare a mycelium culture medium of Seriporia laccerata; (b) drying the powdered mycelium culture medium of the seriporia laccerata; And (c) extracting the dry powder of the mycelium culture medium of Seriphoria laccerata with a solvent, filtering the same, and concentrating under reduced pressure.
  • the medium for liquid culture of the mycelia of the seriporia laccerata in step (a) is sugar, glucose, starch, hydrate, soybean meal, soy flour, magnesium sulfate (MgSO 4 ), potassium phosphate (KH 2 PO). 4 ), potassium diphosphate (K 2 HPO 4 ) and water, and the hydrogen ion concentration may be pH 4.5 ⁇ 6.0.
  • the medium 0.2 to 3% by weight of sugar, 0.2 to 3% by weight of glucose, 0.2 to 4% by weight, 0.1 to 0.5% by weight of water, 0.1 to 0.5% by weight of wheat flour, 0.2 to 3 weight of soy flour %, 0.01% to 0.1% by weight of magnesium sulfate (MgSO 4 ), 0.01% to 0.25% by weight of potassium monophosphate (KH 2 PO 4 ), 0.01% to 0.25% by weight of potassium diphosphate (K 2 HPO 4 ) and the balance of water Can be.
  • MgSO 4 magnesium sulfate
  • KH 2 PO 4 potassium monophosphate
  • K 2 HPO 4 potassium diphosphate
  • Liquid culture in the step (a) may be carried out by maintaining the concentration of carbon dioxide under 1,000 to 2,000 ppm under a blue LED light source.
  • the liquid culture for example, at 20 ⁇ 28 °C hydrogen ion concentration (pH) of 4.5 to 6.0, the light source to maintain a blue LED, 0.1 to 0.8 LUX illuminance, 0.5 to 2.0 kgf / cm2 air injection
  • the concentration of carbon dioxide may be performed for 8 to 13 days while maintaining the concentration at 1,000 to 2,000 ppm. Specifically, it may be performed for 5 to 15 days at the conditions of 20 ⁇ 25 °C, pH 4.5 ⁇ 6.0, 0.5 ⁇ 2.0 kgf / cm2, and 1,000 ⁇ 2,000 ppm.
  • the content of the extracellular polysaccharide produced is high.
  • the parent strain in the step (a) is about one excellent strain stored at 1 ⁇ 5 °C in PDA (Potato dextrose agar) medium state, using a PDB (Potato dextrose broth) medium in an Erlenmeyer flask, about 25 in shake incubator It can be used after incubating for 7-9 days while maintaining the temperature of °C.
  • the culture solution or mycelium obtained after culturing the parent strain can be used as the inoculum.
  • the amount of mycelium to be added to the inoculum may be about 0.5% (w / v) based on the amount of the solution to be cultured.
  • the amount of extracellular polysaccharides does not increase as the amount of mycelia (% / 100 ml, w / v) increases, so the medium composition has the highest content of extracellular polysaccharides, not the best nutritional ratio and environmental conditions for the growth of mycelia. It is preferable to apply the selective culture conditions to form.
  • the culture solution can be separated and purified into a mycelium and an aqueous solution.
  • the solution from which the mycelium is removed by centrifugation may be repeatedly purified using a multi-sheet filter press and a vibration centrifugal separator (PALLSEP), and then irradiated with ultraviolet (UV) light for 1 minute.
  • the culture solution may be stored after sealing to remove oxygen, which may bring a change in the content of the active ingredient due to the growth of the mycelia when the mycelia exist in the culture solution.
  • the mycelium culture solution prepared in step (a) may be dried and powdered.
  • the drying may be performed for 48 to 96 hours at a temperature of 40 °C or less, more specifically 30 °C or less to prevent the disappearance of the active material.
  • the drying is preferable to use a vacuum freeze dryer rather than a vacuum dryer to set the evaporation temperature relatively high because the change in the effective substance content is minimized.
  • step (c) after extracting the dry powder of the mycelium culture medium obtained in step (b) with a solvent, the extracellular polysaccharide which is an active ingredient of the composition according to the present invention is separated.
  • the extraction solvent may be a solvent selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, acetone, ether, chloroform and ethyl acetate or a mixed solvent thereof, and more specifically, water, methanol, ethanol, butanol It may be a solvent selected from the group consisting of acetone and ethyl acetate or a mixed solvent thereof, and more specifically, may be water or 50 to 80% (v / v) ethanol aqueous solution.
  • the pharmaceutical composition of the present invention exhibits the effect of preventing or eliminating hangovers by reducing blood ethanol and / or acetaldehyde concentration.
  • the extracellular polysaccharide may be included in 0.1 to 80% by weight, specifically, 0.1 to 50% by weight relative to the total weight of the pharmaceutical composition.
  • the pharmaceutical composition may appropriately include a mycelium culture medium, a dry powder thereof, or an extract of the mycelium culture medium of Seriphoria laccerata in an amount corresponding to the content of the extracellular polysaccharide.
  • the effective amount of the extracellular polysaccharide, the culture solution containing the same, the dry powder of the culture solution or the extract of the culture solution may be appropriately adjusted according to the method of use and purpose of the pharmaceutical composition.
  • the pharmaceutical composition is an extracellular polysaccharide produced by Seriphoria laccerata, mycelium culture medium of the Seriphoria laccerata, containing the dry powder of the mycelium culture medium or extract of the mycelium culture medium as an active ingredient
  • it may further include suitable carriers, excipients and diluents commonly used in the pharmaceutical art.
  • compositions according to the invention may be formulated according to conventional methods. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories, and the like.
  • compositions according to the invention can be prepared in suitable formulations using pharmaceutically inert organic or inorganic carriers. That is, when the formulation is a tablet, coated tablet, dragee and hard capsule, it may include lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof. In addition, when the formulation is a soft capsule, it may include polyols of vegetable oils, waxes, fats, semisolids and liquids. Furthermore, when the formulation is in the form of a solution or syrup, it may include water, polyols, glycerol, and / or vegetable oils and the like.
  • the pharmaceutical composition according to the present invention may further include a preservative, a stabilizer, a humectant, an emulsifier, a solubilizer, a sweetener, a colorant, an osmotic agent, an antioxidant, and the like in addition to the carrier.
  • the method of administering the pharmaceutical composition according to the present invention can be easily selected according to the dosage form, and can be administered orally or parenterally.
  • the dosage may vary depending on the age, sex, weight, severity, and route of administration of the patient, but generally 5 to 1,000 mg per kilogram of body weight, specifically 10 to 600, based on the extracellular polysaccharide as an active ingredient.
  • the mg may be administered once to three times daily.
  • the above dosage does not limit the scope of the present invention.
  • the pharmaceutical composition according to the present invention not only provides excellent hangover relieving effect but also has little toxicity and side effects due to the drug, so that it can be used with confidence even during long-term use.
  • the present invention is an extracellular polysaccharide produced by Seriphoria laccerata, mycelium culture medium of the Seriporia laccerata containing the extracellular polysaccharide, the dry powder of the mycelium culture medium or the extract of the mycelium culture medium active ingredient It provides a health functional food for preventing or improving the hangover.
  • the extracellular polysaccharide, mycelium culture medium of the three liporia laccerata containing the same, its dry powder or extract is as described above.
  • the dietary supplement according to the present invention may be in the form of a powder, granule, tablet, capsule or beverage.
  • the health functional food according to the present invention may be candy, chocolate, gum, tea, vitamin complex, health supplements and the like.
  • the dietary supplement is an extracellular polysaccharide of the present invention, a food supplement that is acceptable in food supplements with a mycelium culture medium of Seriphoria laccerata containing the extracellular polysaccharide, a dry powder of the mycelium culture medium or an extract of the mycelium culture medium. It may further include.
  • the health functional food may have an excellent hangover relief effect.
  • Health functional food according to the present invention can be ingested with confidence even in the long-term taking as well as the above-described effects, there is little toxicity and side effects.
  • the extracellular polysaccharide produced by the seriporia laccerata of the present invention, the mycelium culture medium of the seriporia laccerata containing the same, the dry powder of the mycelium culture medium or the extract of the mycelium culture solution is hangover prevention and / or hangover It can be used as an additive in various medicines, quasi-drugs and foods for the purpose of showing the relieving effect, wherein the amount and the use form can be appropriately adjusted according to the purpose.
  • the present invention is an extracellular polysaccharide produced by the above-mentioned Ceriporia laccerata, mycelium culture medium of the Ceriporia laccerata containing the extracellular polysaccharide, dry powder of the mycelium culture medium or the mycelium culture medium.
  • methods for preventing or eliminating hangovers comprising administering an extract to a subject in need thereof.
  • the subject may be a mammal, specifically a human.
  • the present invention is an extracellular polysaccharide produced by the above-mentioned Ceriporia laccerata, for use in the preparation of a hangover prevention or remedy composition, of the Ceriporia laccerata comprising the extracellular polysaccharide
  • Ceriporia laccerata comprising the extracellular polysaccharide
  • a mycelium culture solution, a dry powder of the mycelium culture solution or an extract of the mycelium culture solution is provided.
  • PDB Potato dextrose broth
  • Difco Becton Dickinson and Company
  • the mycelium culture medium of Ceriporia laccerata was prepared by liquid culture of the Ceriporia laccerata mycelium at a constant temperature of 23 ° C. for 10 days.
  • the mycelium culture medium of Ceriporia laccerata prepared in Preparation Example 1.1 was vacuum-dried and powdered by vacuum freeze drying at 25 ° C. for 72 hours using a vacuum freeze dryer to prepare a dry powder of the mycelium culture medium of Ceriporia laccerata.
  • the extract of the mycelium culture medium of Seriphoria laccerata prepared in Preparation Example 1.3 was further centrifuged at 8,000 rpm for 20 minutes, and the precipitate was recovered to obtain a crude EPS.
  • the crude EPS was vacuum-dried at 25 ° C. for 72 hours using a vacuum freeze dryer to obtain EPS produced by Ceriporia laccerata.
  • the EPS prepared in Preparation Example 1 was dissolved in 0.1 M Na 2 SO 4 /0.05 M NaN 3 (adjust the pH to 4 with glacial acetic acid) to 1% (w / v) and then at 4,000 rpm. After centrifugation for 0.5 hour, only the supernatant was filtered with a 0.45 ⁇ m syringe filter and analyzed by GPC.
  • the GPC analysis conditions using the refractive index as a detector GPC column using a OHpak SB 805 HQ (Shodex, Japan) 0.1 M Na 2 SO 4 /0.05 M NaN 3 (mobile pH to pH 4 as glacial acetic acid) ), And the flow rate of the mobile phase was flowed at a rate of 1.0 mL / minute.
  • Standard curves were prepared using Dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa, or 1200 kDa), and Knauer K-2310 (refractive index (RI) measuring instrument). Germany) to determine the molecular weight of the EPS.
  • the measurement conditions are summarized in Table 1 below.
  • the molecular weight of EPS of the present invention was found to be about 120 kDa.
  • the EPS prepared in Preparation Example 1 was second-purified and treated with proteolytic enzymes to determine sugar and protein content.
  • the super purified EPS (EPS prepared in Preparation Example 1) was dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant. Ethanol corresponding to 2-3 times the volume of the supernatant was added to the separated supernatant and placed in a 4 ° C. refrigerator for 12 hours. Thereafter, only the supernatant was again centrifuged at 8,000 rpm for 20 minutes in the stationary material, and the precipitate was recovered to obtain a second purified EPS.
  • the second purified EPS was dissolved in distilled water, and the proteolytic enzyme alcalase was treated at 50 ° C. for 30 minutes at a concentration of 0.5% (w / v).
  • Sugar content was measured using the phenol-sulfuric acid method. Specifically, 25 ⁇ l of 80% (w / v) phenol was added to 1 mL of the sample diluted by concentration, and then 2.5 mL of sulfuric acid was added and cooled to room temperature. The absorbance was measured at 465 nm to calculate the sugar content.
  • the protein content was measured by the BCA method (Smith PK et al. , Analytical Biochemistry , 150 (1): 76-85, 1985), and bovine serum albumin was used as a standard.
  • the sugar content and protein content measured as described above are shown in Table 2 below, and the sugar content was found to be 45 to 51 wt% and the protein content was 33 to 34 wt%.
  • EPS mainly contains mannose, galactose and glucose.
  • mice were treated with ethanol, treated with various concentrations of the Ceriphoria laccerata mycelium culture medium, and the concentration of blood alcohol in the mouse was measured. It was.
  • the first group received only distilled water as a normal control group
  • the second group received oral administration of 40% (v / v) ethanol at an amount of 5 g / kg body weight as a negative control group
  • the third group as an experimental group.
  • 40% (v / v) ethanol and 100 mg / kg body weight of 5 g / kg body weight were orally administered with the culture medium of Ceriporia laccerata of Preparation Example 1.1
  • the fourth group was 5 g as the experimental group.
  • 40% (v / v) ethanol and 500 mg / kg body weight of the amount of the weight of the weight of the culture medium of Ceriporia lacserata of Preparation Example 1.1 was administered orally.
  • the blood ethanol concentration was 10.76 and 3, respectively, the group 3 and the fourth group added to the culture medium of the seriporia lacserata mycelium compared to the second group administered only ethanol, respectively. % And 7.03% lower.
  • the third and fourth groups were 54.46% and 84.04% lower than the second group to which only ethanol was administered.
  • the AUC of the second group was 1398.9 mM ⁇ min
  • the AUC of the third group was 1238.7 mM ⁇ min
  • the AUC of the fourth group was 1195.05. mM ⁇ min.
  • the mycelium culture medium of the seriporia laccerata of the present invention reduces the concentration of ethanol in the blood, and thus the mycelial culture solution of the seriporia laccerata has a hangover effect.
  • the drug group is 90.91% by weight dry powder of Ceriporia laccerata mycelium culture medium of Preparation Example 1.2, 6.49% by weight crystalline cellulose, silicon dioxide 1.8
  • Two tablets (550 mg / tablet) made of a mixture of wt% and 0.8 wt% magnesium stearate were administered orally, and the placebo group was a tablet made of a mixture of lactose (550 mg / tablet) instead of dry powder of Ceriporia laccerata mycelia. ) was administered orally.
  • the blood alcohol concentration of the panel was measured immediately after drinking, 30 minutes after, 60 minutes after, 120 minutes and after 16 hours, and the measurement was performed using a breathalyzer measuring blood levels by expiration.
  • 16 hours after drinking the panel was subjected to a clinical questionnaire.
  • the relative concentration (%) of blood ethanol measured as a reference (100%) immediately after drinking is shown in Table 4 and FIG. 2, and the average value of the clinical questionnaire results after drinking 16 hours is shown in Table 5 below.
  • the blood ethanol concentration after drinking was 23.08% and 9.23% after 60 minutes and 120 minutes of drinking in the medicament group administered the culture medium of the seriporia laccerata mycelium of the present invention compared to the placebo group. Low.
  • the AUC of the drug group was 584.62 relative% x time
  • the AUC of the placebo group was 645.75 relative% x time.
  • the Jinja group had direct hangover-related symptoms (24% relief and 39% relief from thirst), fatigue-related symptoms (32% relief of helplessness and 43% relief of drowsiness) due to hangover, and hangover.
  • Arousal-related symptoms relieves 38% of difficulty in weathering and 32% reduction in concentration
  • digestive-related symptoms from hangovers (33% relief from abdominal pain)
  • headache-related symptoms from hangovers (relieves headaches 38% and dizziness 23%) Improved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un polysaccharide extracellulaire produit à partir de Ceriporia lacerata, un milieu de culture de mycélium de Ceriporia lacerata contenant le polysaccharide extracellulaire, et une composition pour soulager la gueule de bois contenant une poudre sèche ou un extrait du milieu de culture de mycélium comme principe actif. La composition selon la présente invention réduit la concentration d'éthanol ou d'acétaldéhyde dans le sang et est donc excellente pour soulager la gueule de bois.
PCT/KR2016/011183 2015-10-08 2016-10-06 Composition pour soulager la gueule de bois contenant un polysaccharide extracellulaire fabriqué à partir de ceriporia lacerata comme principe actif WO2017061787A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150141422A KR101655882B1 (ko) 2015-10-08 2015-10-08 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 숙취해소용 조성물
KR10-2015-0141422 2015-10-08

Publications (1)

Publication Number Publication Date
WO2017061787A1 true WO2017061787A1 (fr) 2017-04-13

Family

ID=56950591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/011183 WO2017061787A1 (fr) 2015-10-08 2016-10-06 Composition pour soulager la gueule de bois contenant un polysaccharide extracellulaire fabriqué à partir de ceriporia lacerata comme principe actif

Country Status (2)

Country Link
KR (1) KR101655882B1 (fr)
WO (1) WO2017061787A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925096B1 (ko) 2018-05-02 2018-12-04 아미코젠주식회사 숙취해소효소 분말의 제조방법 및 이를 포함하는 숙취해소용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101031605B1 (ko) * 2010-11-11 2011-04-27 김병천 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물
US20140193454A1 (en) * 2013-01-09 2014-07-10 Byoung Cheon KIM Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient
KR101444614B1 (ko) * 2013-08-01 2014-09-26 계명대학교 산학협력단 세리포리아 락세라타 및 젖산균의 혼합배양을 통한 ｇａｂａ가 증진된 발효물 제조방법
KR101522415B1 (ko) * 2015-02-26 2015-05-21 한상선 세리포리아 락세라타 추출물을 포함하는 화장료 조성물 및 이를 이용한 화장품
KR20150103690A (ko) * 2013-01-18 2015-09-11 (주)퓨젠바이오농업회사법인 세리포리아 라세라타 배양액 추출물의 제조방법 및 이로부터 제조된 세리포리아 라세라타 배양액 추출물을 유효성분으로 함유하는 당뇨성 질환 및 당뇨 합병증의 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100968109B1 (ko) 2008-01-15 2010-07-06 주식회사농심 칼슘 화합물을 주성분으로 한 천연 원료의 숙취 해소용조성물 및 이의 제조 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101031605B1 (ko) * 2010-11-11 2011-04-27 김병천 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물
US20140193454A1 (en) * 2013-01-09 2014-07-10 Byoung Cheon KIM Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient
KR20150103690A (ko) * 2013-01-18 2015-09-11 (주)퓨젠바이오농업회사법인 세리포리아 라세라타 배양액 추출물의 제조방법 및 이로부터 제조된 세리포리아 라세라타 배양액 추출물을 유효성분으로 함유하는 당뇨성 질환 및 당뇨 합병증의 예방 또는 치료용 약학적 조성물
KR101444614B1 (ko) * 2013-08-01 2014-09-26 계명대학교 산학협력단 세리포리아 락세라타 및 젖산균의 혼합배양을 통한 ｇａｂａ가 증진된 발효물 제조방법
KR101522415B1 (ko) * 2015-02-26 2015-05-21 한상선 세리포리아 락세라타 추출물을 포함하는 화장료 조성물 및 이를 이용한 화장품

Also Published As

Publication number Publication date
KR101655882B1 (ko) 2016-09-08

Similar Documents

Publication Publication Date Title
WO2012020892A1 (fr) Extrait de rhus verniciflua stokes ayant une teneur augmentée de composé flavonoïde actif et procédé pour préparer celui-ci
WO2014084572A1 (fr) Agent améliorant la biodisponibilité de la catéchine comprenant de la cyclodextrine
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2021230581A1 (fr) Découverte d'une nouvelle akkermansia muciniphila ak32 et application correspondante pour la prévention ou le traitement d'une lésion intestinale
WO2021125822A1 (fr) Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif
WO2010107170A1 (fr) Composition pour traiter des maladies métaboliques
WO2017061769A1 (fr) Composition de prévention de l'alopécie ou de stimulation de la croissance capillaire contenant un polysaccharide extracellulaire produit par ceriporia lacerata en tant qu'ingrédient actif
WO2016085290A1 (fr) Composition antioxydante contenant un polysaccharide extracellulaire produit à l'aide de ceriporia lacerata comme principe actif
WO2022145893A1 (fr) Composition permettant de soulager le stress comprenant du noni et du calamondin fermentés et vieillis comme principes actifs
WO2021167356A1 (fr) Agent de soulagement de la veisalgie contenant du glutathion et de l'aldéhyde déshydrogénase
WO2017023070A1 (fr) Composition favorisant la récupération de la fatigue contenant, comme principe actif, des polysaccharides extracellulaires produits par ceriporia lacerate
WO2016010182A1 (fr) Composition permettant d'améliorer une fonction hépatique comprenant comme principe actif un exopolysaccharide dérivé d'un extrait de milieu de culture de ceriporia lacerata
WO2007009392A1 (fr) Utilisation d'acide chlorogenique dans la fabrication de medicaments pour le traitement et/ou la prevention de trouble hepatique
WO2017061787A1 (fr) Composition pour soulager la gueule de bois contenant un polysaccharide extracellulaire fabriqué à partir de ceriporia lacerata comme principe actif
WO2016072697A1 (fr) Composition faisant baisser la tension artérielle et contenant en tant que principe actif un exopolysaccharide produit à l'aide de ceriporia lacerata
WO2016072710A1 (fr) Composition tranquillisante contenant, en tant que principe actif, un exopolysaccharide produit à l'aide de ceriporia lacerata
WO2021242057A1 (fr) Souche de lactobacillus sp., reticulum endoplasmique dérivé de cette dernière, et utilisation anti-inflammatoire et antibactérienne associée
WO2021242056A1 (fr) Souche de l'espèce bifidobacterium et vésicule extracellulaire dérivée de cette dernière, et leurs utilisations anti-inflammatoires et antibactériennes
WO2017061819A1 (fr) Composition pour améliorer la circulation sanguine contenant comme principe actif un polysaccharide extracellulaire produit à partir de ceriporia lacerata
WO2017142306A1 (fr) Composition pharmaceutique pour prévenir ou traiter les maladies dégénératives du cerveau, contenant un polysaccharide extracellulaire produit par ceriporia lacerata en tant que principe actif
WO2019078570A2 (fr) Composition pour soulager la gueule de bois contenant un conjugué sésamol-peptide à titre de principe actif
WO2020004858A1 (fr) Composition pour soulager le diabète ou antioxydante comprenant un extrait de levure et procédé de préparation d'extrait de levure
KR101734909B1 (ko) 갯질경의 신규 용도
WO2019212202A1 (fr) Composition pour la protection du foie comprenant un extrait de curcuma et un extrait fermenté de soja et de germes de riz
KR101737626B1 (ko) 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 과잉 면역 억제용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16853903

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/08/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16853903

Country of ref document: EP

Kind code of ref document: A1